Moneycontrol
HomeNewsBusinessIPOAs a promoter I am bound to provide capital adequacy to Star Health Insurance, says Rakesh Jhunjhunwala
Trending Topics

As a promoter I am bound to provide capital adequacy to Star Health Insurance, says Rakesh Jhunjhunwala

"I think we have an excellent management and excellent leader. So why should I interfere when you know things have been managed well. I have no worries on that count."

December 10, 2021 / 14:37 IST
Story continues below Advertisement

Star Health IPO | Promoter Rakesh Jhunjhunwala is the second largest shareholder in the company.

Ace investor Rakesh Jhunjhunwala, partner in Rare Enterprises, is also the promoter of Star Health and Allied Insurance Company Limited, which made its stock market debut on Friday, December 10, at a discount to its sale price. Moneycontrol’s Nisha Poddar caught up with Jhunjhunwala to hear his insights on value creation by Star Health and his views on equity market investments. Edited excerpts:

Star Health’s listing is a big milestone for you personally; you are the company’s promoter. What does this mean to you?
It is part of life. We invested about 30 months back and now it is listed and I am hopeful it will do well. As a promoter of an insurance company I am bound to provide capital adequacy to it. Responsibility of being a promoter of insurance company goes far beyond the normal promoter requirements.

Over the last two years, health insurance has gained in terms of prominence; it has also taken a lot of the load of  COVID-19 as well. What do you suggest will be the long-term value creation metrics for Star Health?
...just about 15% of the amount people spend on healthcare in India is through the means of insurance. In advanced countries, about 80% is paid by insurance. So it's a nascent industry in India. And Star Health has got a 31% market share in retail health insurance in India. I think this kind of domination in any industry which is poised to grow is very rare. So I remain optimistic and hopeful and that is why I haven't sold any shares in the issue.

Star Health’s was a fiercely competitive bid process when you bought it and you have made returns on the valuation. Give us some details about the kind of growth versus profitability balance that this company is going to see because that will be an important aspect for investors who bet on risk-reward parameters.
It was an intensely complicated process. There was a dispute between the promoters who were to sell to us, and I think it took 18 months for us to complete the transaction. Growth without profitability is no purpose, so the essential idea is to earn a profit, and COVID-19 is a once-in-a-lifetime situation. I don't need think it will occur again. In my opinion, it's all dead, except the noise.

COVID-related losses have burdened the health insurance sector and uncertainty has cropped up because of the Omicron variant. Since the time you issue launched this issue to now, the world is slightly different in terms of uncertainty as well as market volatility. Do you think that has a bearing on the valuation of Star Health?

Story continues below Advertisement

Not in my mind, but surely near-term factors do affect people's perception of valuation. And it has affected the valuation to some extent. But I see the price at more than Rs. 900.

How do you see the growth momentum as a promoter? What will be key areas to watch out for in terms of management and operations?